2-(4-(tert-Butyl)phenyl)-1H-benzo[d]imidazole

Catalog No. :
ACFRES630
CAS No. :
49671-76-3
Molecular Formula :
C17H18N2
Molecular Weight :
250.35

IUPAC Name:2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole

2-(4-(tert-Butyl)phenyl)-1H-benzo[d]imidazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$50.00Login to see priceIn stockInquiry
250mg97%$74.00Login to see priceIn stockInquiry
1g97%$209.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(4-(tert-Butyl)phenyl)-1H-benzo[d]imidazole
IUPAC Name2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole
MDL No.MFCD01560221
Molecular FormulaC17H18N2
Molecular Weight250.35
SMILESCC(C1=CC=C(C2=NC3=CC=CC=C3N2)C=C1)(C)C
InChI KeyLQUNNCQSFFKSSK-UHFFFAOYSA-N
SynonymZLN005 | 49671-76-3 | 2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole | 2-(4-tert-butylphenyl)-1H-benzimidazole | 2-(4-tert-butylphenyl)-1H-benzo[d]imidazole | CBMicro_034305 | SCHEMBL6755306 | CHEMBL4303368 | DTXSID60358473 | EX-A690 | TQS-168 | ZLN 005 | ZLN-005 | 3WT26285WB | HMS36
CAS No.49671-76-3
PubChem CID899323

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P305+P351+P338

Synthetic Route by SureRoute

1. ACFRES630 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHBYM062 route compound structure diagram
    ACHBYM062123324-71-0 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFRES630 route product structure diagram
    ACFRES63049671-76-3 In Stock
Inquiry

2. ACFRES630 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFRES630 route product structure diagram
    ACFRES63049671-76-3 In Stock
Inquiry

Comments (0)